| Literature DB >> 28965757 |
Prajwal Boddu1, Christopher B Benton1, Wei Wang2, Gautam Borthakur1, Joseph D Khoury3, Naveen Pemmaraju4.
Abstract
Acute erythroleukemia is a rare form of acute myeloid leukemia recognized by its distinct phenotypic attribute of erythroblastic proliferation. After a century of its descriptive history, many diagnostic, prognostic, and therapeutic implications relating to this unique leukemia subset remain uncertain. The rarity of the disease and the simultaneous involvement of its associated myeloid compartment have complicated in vitro studies of human erythroleukemia cell lines. Although murine and cell line erythroleukemia models have provided valuable insights into pathophysiology, translation of these concepts into treatment are not forthcoming. Integration of knowledge gained through a careful study of these models with more recent data emerging from molecular characterization will help elucidate key mechanistic pathways and provide a much needed framework that accounts for erythroid lineage-specific attributes. In this article, we discuss the evolving diagnostic concept of erythroleukemia, translational aspects of its pathophysiology, and promising therapeutic targets through an appraisal of the current literature.Entities:
Keywords: Acute erythroleukemia – M6a subtype; Acute erythroleukemia – M6b subtype; Bromodomain protein; Erythroblasts; GATA1 protein; MicroRNA; PU.1 protein; Pure erythroid leukemia; TP53
Mesh:
Year: 2017 PMID: 28965757 PMCID: PMC5857409 DOI: 10.1016/j.blre.2017.09.002
Source DB: PubMed Journal: Blood Rev ISSN: 0268-960X Impact factor: 8.250